Meropenem Kalceks (Meropenem)

Meropenem belongs to the carbapenem class of β‑lactam antibiotics. It binds tightly to penicillin‑binding proteins on the bacterial cell wall, blocking the transpeptidation step needed for peptidoglycan cross‑linking. This inhibition weakens the cell wall, causing osmotic rupture and bacterial cell death, providing rapid bactericidal activity against a wide range of pathogens.

The dosage of Meropenem Kalceks is determined by the prescribing clinician based on the type and severity of infection, the patient’s renal function, age and weight. Typical regimens range from 0.5 g to 2 g administered intravenously every 8 hours, but exact dosing must be individualized by a qualified healthcare professional.

Safety data for Meropenem in pregnancy and lactation are limited. The drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Breastfeeding mothers should consult their physician, as meropenem may be excreted in breast milk and could affect the nursing infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Both Meropenem and Imipenem‑cilastatin are broad‑spectrum carbapenems, but Meropenem is generally more stable against many β‑lactamases and has a slightly broader anaerobic coverage. Imipenem requires co‑administration with cilastatin to inhibit renal dehydropeptidase, whereas Meropenem does not need such protection. Choice depends on local resistance patterns, patient tolerance and specific infection sites.

Meropenem Kalceks should be stored at temperatures below 25 °C (77 °F). Keep the product in its original packaging, protect it from moisture and direct light, and avoid freezing. Once reconstituted, follow the manufacturer’s guidance for stability and discard any unused solution after the recommended period.

Meropenem Kalceks is supplied for intravenous infusion. The powder is reconstituted with a suitable diluent, then further diluted in an infusion bag as directed. It is typically administered over 30 minutes to 1 hour, depending on the clinical protocol, and should be given under aseptic conditions by qualified healthcare personnel.

Serious adverse events include seizures, especially in patients with pre‑existing central nervous system disorders or renal impairment; severe hypersensitivity reactions such as anaphylaxis; Clostridioides difficile‑associated colitis; and significant neutropenia or agranulocytosis. Prompt recognition and discontinuation of the drug are essential if any of these events occur.

Meropenem Kalceks is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation. Caution is also advised for individuals with a history of seizures, severe renal dysfunction, or those receiving valproic acid, as the risk of adverse neurological events may be increased.